N',N''-diacetylspermine: intermediate in polyamine catabolism [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 132679 |
| CHEBI ID | 178484 |
| MeSH ID | M0093934 |
| Synonym |
|---|
| n',n''-diacetylspermine |
| acetamide, n,n'-(1,4-butanediylbis(imino-3,1-propanediyl))bis-, dihydrochloride |
| 77928-71-3 |
| CHEBI:178484 |
| n-[3-[4-(3-acetamidopropylamino)butylamino]propyl]acetamide;dihydrochloride |
| diacetylspermine |
| n1,n12-diacetylspermine dihydrochloride |
| MS-25659 |
| n,n'-[butane-1,4-diylbis(azanediylpropane-3,1-diyl)]diethanimidic acid--hydrogen chloride (1/2) |
| DTXSID20999129 |
| n,n'-[1,4-butanediylbis(imino-3,1-propanediyl)]bis-acetamide, dihydrochloride |
| CS-0109683 |
| HY-113374A |
| n1,n12-diacetylspermine (dihydrochloride) |
| n1,n12-diacetylspermine (hydrochloride) |
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (4.17) | 18.7374 |
| 1990's | 7 (14.58) | 18.2507 |
| 2000's | 17 (35.42) | 29.6817 |
| 2010's | 17 (35.42) | 24.3611 |
| 2020's | 5 (10.42) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (4.00%) | 5.53% |
| Reviews | 7 (14.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 41 (82.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| n(1)-acetylspermidine N(1)-acetylspermidine : An acetylspermidine having the acetyl group at the N1-position. | 2.37 | 2 | 0 | acetylspermidine | Escherichia coli metabolite; metabolite |
| malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group. | 2.31 | 1 | 0 | 2-hydroxydicarboxylic acid; C4-dicarboxylic acid | food acidity regulator; fundamental metabolite |
| glycolic acid glycolic acid: RN given refers to parent cpd. glycolic acid : A 2-hydroxy monocarboxylic acid that is acetic acid where the methyl group has been hydroxylated. | 2.31 | 1 | 0 | 2-hydroxy monocarboxylic acid; primary alcohol | keratolytic drug; metabolite |
| n'-acetylspermine N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1). | 3.23 | 6 | 0 | acetamides; acetylspermine | human metabolite |
| niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. | 2.1 | 1 | 0 | pyridine alkaloid; pyridinecarboxamide; vitamin B3 | anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor |
| orotic acid Orotic Acid: An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE.. orotic acid : A pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6. | 2.31 | 1 | 0 | pyrimidinemonocarboxylic acid | Escherichia coli metabolite; metabolite; mouse metabolite |
| putrescine [no description available] | 2.03 | 1 | 0 | alkane-alpha,omega-diamine | antioxidant; fundamental metabolite |
| spermidine [no description available] | 5.82 | 12 | 0 | polyazaalkane; triamine | autophagy inducer; fundamental metabolite; geroprotector |
| spermine [no description available] | 9.89 | 48 | 2 | polyazaalkane; tetramine | antioxidant; fundamental metabolite; immunosuppressive agent |
| uridine [no description available] | 2.31 | 1 | 0 | uridines | drug metabolite; fundamental metabolite; human metabolite |
| ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5. | 2.13 | 1 | 0 | non-proteinogenic L-alpha-amino acid; ornithine | algal metabolite; hepatoprotective agent; mouse metabolite |
| arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group. | 2.13 | 1 | 0 | arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical |
| homoarginine L-homoarginine : An L-lysine derivative that is the L-enantiomer of homoarginine. | 2.31 | 1 | 0 | homoarginine; L-lysine derivative; non-proteinogenic L-alpha-amino acid | biomarker; EC 3.1.3.1 (alkaline phosphatase) inhibitor; human metabolite; rat metabolite; xenobiotic metabolite |
| gold Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. | 2.06 | 1 | 0 | copper group element atom; elemental gold | |
| n-(gamma-maleimidobutyryloxy)succinimide [no description available] | 2.39 | 2 | 0 | ||
| proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2. | 2.31 | 1 | 0 | amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid | algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| isoputreanine isoputreanine: metabolite of spermidine; RN given refers to parent cpd or spermine in human urine | 1.97 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| n-methylproline N-methylproline: structure in first source. N-methylproline : An L-proline derivative obtained by replacement of the amino hydrogen by a methyl group. | 2.31 | 1 | 0 | L-alpha-amino acid zwitterion; L-proline derivative; tertiary amino compound | human metabolite; plant metabolite |
| nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety. | 2.1 | 1 | 0 | organophosphate oxoanion | cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite |
| s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine. | 2.1 | 1 | 0 | organic cation; sulfonium compound | coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| colibactin colibactin: a hybrid peptide-polyketide secreted by E coli. colibactin : A member of the class of 1,3-thiazoles that comprises of two units of 2-[(2-{6-[(2S)-2-methyl-3,4-dihydro-2H-pyrrol-5-yl]-5-oxo-4-azaspiro[2.4]hept-6-en-7-yl}acetamido)methyl]-1,3-thiazole-4-carboxylic acid linked together via the formal condensation of the carboxy groups. It is a secondary metabolite produced by certain strains of bacteria found in the human gut such as Escherichia coli. It has the ability to bind covalently to DNA and is strongly associated with colorectal cancer. | 2.13 | 1 | 0 | 1,3-thiazoles; azaspiro compound; polyketide; pyrroline; secondary carboxamide | alkylating agent; carcinogenic agent; Escherichia coli metabolite; genotoxin |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Benign Neoplasms [description not available] | 0 | 5.87 | 10 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 5.87 | 10 | 0 |
| ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available] | 0 | 2.25 | 1 | 0 |
| Metastase [description not available] | 0 | 2.25 | 1 | 0 |
| Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. | 0 | 2.25 | 1 | 0 |
| Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN. | 0 | 2.25 | 1 | 0 |
| Lymphoma of Mucosa-Associated Lymphoid Tissue [description not available] | 0 | 2.31 | 1 | 0 |
| Orbital Neoplasms Neoplasms of the bony orbit and contents except the eyeball. | 0 | 2.31 | 1 | 0 |
| Gammapathy, Monoclonal [description not available] | 0 | 2.31 | 1 | 0 |
| Orbital Diseases Diseases of the bony orbit and contents except the eyeball. | 0 | 2.31 | 1 | 0 |
| Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. | 0 | 2.31 | 1 | 0 |
| Lymphoma, B-Cell, Marginal Zone Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder. | 0 | 2.31 | 1 | 0 |
| Left Ventricular Hypertrophy [description not available] | 0 | 2.31 | 1 | 0 |
| Coronary Heart Disease [description not available] | 0 | 2.31 | 1 | 0 |
| Cardiac Failure [description not available] | 0 | 2.31 | 1 | 0 |
| Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. | 0 | 2.31 | 1 | 0 |
| Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. | 0 | 2.31 | 1 | 0 |
| Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality. | 0 | 2.31 | 1 | 0 |
| Cancer of Ovary [description not available] | 0 | 2.15 | 1 | 0 |
| Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. | 0 | 2.15 | 1 | 0 |
| Colorectal Cancer [description not available] | 0 | 3.15 | 5 | 0 |
| Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) | 0 | 4.81 | 12 | 0 |
| Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. | 0 | 3.15 | 5 | 0 |
| Lung Adenocarcinoma [description not available] | 0 | 2.21 | 1 | 0 |
| Carcinoma, Non-Small Cell Lung [description not available] | 0 | 3.22 | 5 | 0 |
| Carcinoma, Epidermoid [description not available] | 0 | 2.54 | 2 | 0 |
| Cancer of Lung [description not available] | 0 | 4.26 | 6 | 0 |
| Lymph Node Metastasis [description not available] | 0 | 2.54 | 2 | 0 |
| Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. | 0 | 2.21 | 1 | 0 |
| Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. | 0 | 3.22 | 5 | 0 |
| Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) | 0 | 2.54 | 2 | 0 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 4.26 | 6 | 0 |
| Cancer of Liver [description not available] | 0 | 3.37 | 2 | 0 |
| Condition, Preneoplastic [description not available] | 0 | 2.08 | 1 | 0 |
| Liver Neoplasms Tumors or cancer of the LIVER. | 0 | 3.37 | 2 | 0 |
| Precancerous Conditions Pathological conditions that tend eventually to become malignant. | 0 | 2.08 | 1 | 0 |
| Impaired Glucose Tolerance [description not available] | 0 | 2.1 | 1 | 0 |
| Diabetes Mellitus, Adult-Onset [description not available] | 0 | 2.1 | 1 | 0 |
| Liver Steatosis [description not available] | 0 | 3.38 | 2 | 0 |
| Insulin Sensitivity [description not available] | 0 | 2.1 | 1 | 0 |
| Leanness [description not available] | 0 | 2.1 | 1 | 0 |
| Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. | 0 | 2.1 | 1 | 0 |
| Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. | 0 | 3.38 | 2 | 0 |
| Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. | 0 | 2.1 | 1 | 0 |
| Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). | 0 | 2.1 | 1 | 0 |
| Glucose Intolerance A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION. | 0 | 2.1 | 1 | 0 |
| Adenocarcinoma, Basal Cell [description not available] | 0 | 2.1 | 1 | 0 |
| Local Neoplasm Recurrence [description not available] | 0 | 4.12 | 3 | 0 |
| Adenocarcinoma A malignant epithelial tumor with a glandular organization. | 0 | 2.1 | 1 | 0 |
| Invasiveness, Neoplasm [description not available] | 0 | 2.11 | 1 | 0 |
| Cancer of Colon [description not available] | 0 | 5.93 | 5 | 1 |
| Colonic Neoplasms Tumors or cancer of the COLON. | 0 | 5.93 | 5 | 1 |
| Breast Cancer [description not available] | 0 | 3.88 | 4 | 0 |
| Breast Neoplasms Tumors or cancer of the human BREAST. | 0 | 3.88 | 4 | 0 |
| Cancer of Prostate [description not available] | 0 | 2.93 | 1 | 0 |
| Prostatic Neoplasms Tumors or cancer of the PROSTATE. | 0 | 2.93 | 1 | 0 |
| Biliary Tract Cancer [description not available] | 0 | 3.63 | 3 | 0 |
| Cancer of Pancreas [description not available] | 0 | 3.63 | 3 | 0 |
| Biliary Tract Neoplasms Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER. | 0 | 3.63 | 3 | 0 |
| Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). | 0 | 3.63 | 3 | 0 |
| Benign Neoplasms, Brain [description not available] | 0 | 2.94 | 1 | 0 |
| Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. | 0 | 2.94 | 1 | 0 |
| Female Genital Neoplasms [description not available] | 0 | 2.94 | 1 | 0 |
| Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). | 0 | 2.94 | 1 | 0 |
| Experimental Neoplasms [description not available] | 0 | 2.03 | 1 | 0 |
| Autoimmune Chronic Hepatitis [description not available] | 0 | 2.94 | 1 | 0 |
| Viral Hepatitis, Human [description not available] | 0 | 2.94 | 1 | 0 |
| Liver Dysfunction [description not available] | 0 | 2.94 | 1 | 0 |
| Hepatitis, Viral, Human INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). | 0 | 2.94 | 1 | 0 |
| Liver Diseases Pathological processes of the LIVER. | 0 | 2.94 | 1 | 0 |
| Hepatitis, Autoimmune A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES. | 0 | 2.94 | 1 | 0 |
| Bladder Cancer [description not available] | 0 | 2.03 | 1 | 0 |
| Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. | 0 | 2.03 | 1 | 0 |
| Cerebro-Hepato-Renal Syndrome [description not available] | 0 | 1.97 | 1 | 0 |
| Zellweger Syndrome An autosomal recessive disorder due to defects in PEROXISOME biogenesis which involves more than 13 genes encoding peroxin proteins of the peroxisomal membrane and matrix. Zellweger syndrome is typically seen in the neonatal period with features such as dysmorphic skull; MUSCLE HYPOTONIA; SENSORINEURAL HEARING LOSS; visual compromise; SEIZURES; progressive degeneration of the KIDNEYS and the LIVER. Zellweger-like syndrome refers to phenotypes resembling the neonatal Zellweger syndrome but seen in children or adults with apparently intact peroxisome biogenesis. | 0 | 1.97 | 1 | 0 |
| Leukemia L 1210 [description not available] | 0 | 1.97 | 1 | 0 |